OEL Fastrac Catalog

Guanosine is a purine nucleoside with important functions in cell metabolism and a protective role in response to degenerative disease or injury thought to have neuroprotective properties. It is release in the brain under physiological conditions and during pathological events, reducing neuroinflammation, oxidative stress, excitotoxicity, and exerts trophic effects in neuronal and glial cells. Guanosine is a purine nucleoside in which guanine is linked to a ribofuranose ring by a beta- N9-glycosidic bond. Guanosine can be phosphorylated to become guanosine monophosphate, cyclic guanosine monophosphate, guanosine diphosphate (GDP), and guanosine triphosphate, which are factors in signal transduction pathways. The exact mechanism of action by which guanosine exert its neuroprotective properties remains to be fully elucidated but studies have shown that the biological effects are unrelated to direct G-proteins modulations but associated with the modulation of the glutamatergic and adenosinergic systems, trophic effects on neural cells and anti-apoptotic activity.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Guanosine, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.